CG Oncology (CGON) EV/EBITDA: History & Chart

CG Oncology Inc.(CGON)

Biotechnology · Dallas, TX

$63.64-5.07 (-7.38%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About CG Oncology Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Dallas, TX

142 employees

cgoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur Kuan

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
CG Oncology Inc. (CGON)	$5.61B	N/A	N/A	N/A	N/A
RadNet, Inc. (RDNT)vs ›	$5.53B	21.70x	24.95x	22.12x	17.84x
MiniMed Group, Inc. Common Stock (MMED)vs ›	$5.52B	30.67x	33.01x	33.01x	33.01x
Kodiak Sciences Inc. (KOD)vs ›	$5.78B	N/A	N/A	N/A	N/A
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.79B	N/A	N/A	N/A	N/A
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.87B	55.94x	88.38x	133.43x	103.02x
GRAIL Inc. (GRAL)vs ›	$5.89B	N/A	N/A	N/A	N/A
PTC Therapeutics, Inc. (PTCT)vs ›	$5.32B	28.93x	14.09x	107.60x	107.60x
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.95B	45.02x	617.82x	545.60x	321.06x
CRISPR Therapeutics AG (CRSP)vs ›	$5.21B	N/A	12.99x	275.14x	275.14x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

CG Oncology Inc. (CGON)

$5.61B

N/A

RadNet, Inc. (RDNT)vs ›

$5.53B

21.70x

24.95x

22.12x